If you have been reading about prohibited list and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid as supplied |
| Water solubility | Soluble | Dissolves in aqueous media |
| Typical storage temperature | -20 °C | Dry powder, desiccated, protected from light |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity from peak area; mass for identity |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies by supplier and catalogue |
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
The Centers for Medicare & Medicaid Services (CMS) is a federal agency within the United States Department of Health and Human Services (HHS) that administers the Medicare program and works in partnership with state governments to administer Medicaid, the Children's Health Insurance Program (CHIP), and health insurance portability standards. In addition to these programs, CMS has other responsibilities, including the administrative simplification standards from the Health Insurance Portability and Accountability Act of 1996 (HIPAA), quality standards in long-term care facilities (more commonly referred to as nursing homes) through its survey and certification process, clinical laboratory quality standards under the Clinical Laboratory Improvement Amendments, and oversight of HealthCare.gov. CMS was previously known as the Health Care Financing Administration (HCFA) until 2001. CMS actively inspects and reports on every nursing home in the United States. This includes maintaining the 5-Star Quality Rating System.
In addition to his academic work, Baran also holds many accolades in industry as a scientific entrepreneur, company co-founder, consultant and scientific advisor. He co-founded his first company Sirenas Marine Discovery in 2012 alongside Eduardo Esquenazi and Jake Beverage —a company that is focused on marine-inspired small molecules and pre-clinical leads for cancer, HIV, and infectious diseases. In 2016, he joined forces with fellow Scripps colleagues, Benjamin F. Cravatt and Jin-Quan Yu to co-found Vividion Therapeutics with the goal of identifying small molecules that bind currently undrugged targets via a covalent-first chemoproteomics approach. Vividion was sold to Bayer in 2021 for up to $2 billion ($1.5 billion with an additional $500 million in milestone payments). In the same year, Baran founded Elsie Biotechnologies, an antisense oligonucleotide (ASO)-based company with the goal of discovering therapeutic agents that can achieve desirable medicinal effects not attainable with existing drugs by modulating gene expression of DNA or RNA. Elsie Biotechnologies was sold to GlaxoSmithKline (GSK) in 2024 for $50 million. Baran also co-founded and is on the scientific advisory team of Galileo Biosystems, a preclinical stage biopharmaceutical company focused on developing therapeutic agents for inflammatory and autoimmune diseases.
=== Hydrogel-forming microneedles === The primary material for the fabrication of hydrogel-forming microneedles (HFMs) is hydrophilic polymer that encloses drugs. This material draws water from interstitial fluid in the stratum corneum and results in polymer swelling and release of drug. Besides, the hydrophilic features of HFMs allow readily uptake of interstitial fluid that could be used for disease diagnosis.
Sources: en.wikipedia.org
Pharmacy is the science and practice of dispensing, preparing, reviewing safety and efficacy, monitoring, discovering, producing, and consulting about medications, aiming to ensure the safe, effective, and affordable use of medicines. It is an interdisciplinary science as it links health sciences, pharmaceutical sciences, and natural sciences with the humanities. The professional practice is clinically oriented, with most drugs now being manufactured by pharmaceutical industries and prescribed in the medical setting. Based on the setting, pharmacy practice is either classified as community or institutional pharmacy. Providing direct patient care is considered clinical pharmacy, mainly practiced in institutions like hospitals, long-term care facilities, hospice, ambulatory clinics, or psychiatric hospitals. However, more clinical application are becoming important in the community setting to combat barriers to accessing healthcare (e.g., immunizations, point of care testing, oral contraceptive prescribing, administering injectable therapies, suggesting OTC products, or prescribing under Physician backed protocols). The scope of pharmacy practice includes more traditional roles such as dispensing and compounding of medications based on compendiums, like the USP. It also includes more modern services related to health care including clinical services involving medical guideline appropriateness, reviewing medications for safety and efficacy, and providing drug information with patient counselling.
== Further reading == Ye, Yanqi; Yu, Jicheng; Gu, Zhen (2015). "Versatile Protein Nanogels Prepared by In Situ Polymerization". Macromolecular Chemistry and Physics. 217 (3): 333–343. doi:10.1002/macp.201500296. Yan, Ming; Ge, Jun; Liu, Zheng; Ouyang, Pingkai (2006). "Encapsulation of Single Enzyme in Nanogel with Enhanced Biocatalytic Activity and Stability". Journal of the American Chemical Society. 128 (34): 11008–9. Bibcode:2006JAChS.12811008Y. doi:10.1021/ja064126t. PMID 16925402. Reese, Chad E.; Mikhonin, Alexander V.; Kamenjicki, Marta; Tikhonov, Alexander; Asher, Sanford A. (2004). "Nanogel Nanosecond Photonic Crystal Optical Switching". Journal of the American Chemical Society. 126 (5): 1493–6. Bibcode:2004JAChS.126.1493R. doi:10.1021/ja037118a. PMID 14759207. Lee, Eun Seong; Kim, Dongin; Youn, Yu Seok; Oh, Kyung Taek; Bae, You Han (2008). "A Virus-Mimetic Nanogel Vehicle". Angewandte Chemie International Edition. 47 (13): 2418–21. Bibcode:2008ACIE...47.2418L. doi:10.1002/anie.200704121. PMC 3118583. PMID 18236507. Hasegawa, Urara; Nomura, Shin-Ichiro M.; Kaul, Sunil C.; Hirano, Takashi; Akiyoshi, Kazunari (2005). "Nanogel-quantum dot hybrid nanoparticles for live cell imaging". Biochemical and Biophysical Research Communications. 331 (4): 917–21. Bibcode:2005BBRC..331..917H. doi:10.1016/j.bbrc.2005.03.228. PMID 15882965. Du, Jin-Zhi; Sun, Tian-Meng; Song, Wen-Jing; Wu, Juan; Wang, Jun (2010). "A Tumor-Acidity-Activated Charge-Conversional Nanogel as an Intelligent Vehicle for Promoted Tumoral-Cell Uptake and Drug Delivery".
By 1986–1987, the Reagan administration increasingly employed public rhetorical challenges that emphasized human rights and political choice as tests of Soviet reform, during which the American president used a symbolic address to gauge the credibility of Gorbachev's agenda. The most overt example occurred when Reagan challenged Gorbachev on June 12, 1987 to go further with his reforms and democratization by tearing down the Berlin Wall. In a speech at the Brandenburg Gate next to the wall, Reagan stated:
The Trump administration has repeatedly deployed federal forces, including active-duty military personnel and federalised National Guard forces, into certain U.S. cities. Trump has given multiple explanations for the deployments, saying they are part of crackdowns on protests, civil unrest, crime, homelessness, and illegal immigration. The actions targeted Democratic Party-led cities and sparked significant controversy, with critics labeling them as abuses of power and potential violations of laws like the Posse Comitatus Act, which limits military involvement in domestic law enforcement. The moves came amidst broader expansions of the military's domestic use during the second Trump administration, and Trump's prior comments during his presidential campaign to use the military to end civil unrest and protests without consent from state governors and target "the enemy within".During the June 2025 Los Angeles protests against local immigration raids, Trump federalized the California National Guard and deployed them to Los Angeles along with 700 Marines under Joint Task Force 51. Declaring a crime emergency in August 2025, the Trump administration deployed 2,000 National Guard soldiers to Washington, D.C. In September 2025, Trump announced the deployment of 150 unarmed national guardsmen to Memphis, Tennessee, saying that the city "is deeply troubled". Their presence in Memphis started on October 1.
Sources: en.wikipedia.org
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.
The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.
Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.